Streetbeat News

Products Services

MOR

NVS

Morphosys Group Ag expects to complete its acquisition by Novartis in the first half of 2024. Additionally, Morphosys plans to submit a New Drug Application for Pelabresib in combination with Ruxolitinib for Myelofibrosis to the FDA and a Marketing Authorization Application to the European Medicines Agency in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 8:22 pm

PARA

Paramount+ reported a 51% year-over-year revenue increase and surpassed 71 million global subscribers, adding 3.7 million net subscribers in the quarter.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 8:10 pm

RMBS

Rambus Inc. (NASDAQ:RMBS) announced the launch of its new DDR5 server Power Management ICs (PMICs), expanding its chipset offerings for advanced data center memory modules. This new family of PMICs supports high-performance DDR5-based servers, catering to AI and other advanced workloads. The PMICs are part of a complete DDR5 RDIMM memory interface chipset, including RCD, PMIC, SPD Hub, and Temperature Sensor ICs, aiming to meet the growing memory needs of data centers.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 8:10 pm

CLW

Clearwater Paper's CEO, Arsen Kitch, anticipates ongoing strength in tissue performance and a rebound in paperboard demand for the current year. He also believes that customer de-stocking has largely concluded. Additionally, Kitch expressed enthusiasm about finalizing the acquisition of Augusta and welcoming their team to Clearwater Paper.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 8:08 pm

KOPN

Kopin Corporation (NASDAQ:KOPN) has received a third production order for its OLED microdisplays from the Indian Armed Forces, for use in thermal imaging vision systems. The order includes over 1,200 units to be delivered over six months. This expansion into the India defense market signifies a broadening of Kopin's customer base and an increase in its addressable market, highlighting the company's commitment to high performance, quality, and reliable delivery of its products.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 8:05 pm

PARA

Paramount Global announces leadership changes with Bob Bakish stepping down. George Cheeks, Chris McCarthy, and Brian Robbins appointed to lead as Office of the CEO. The new leadership aims to accelerate growth, streamline operations, and optimize streaming strategy. Paramount Global's Board expresses confidence in the new leaders' ability to enhance company performance and value creation.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 8:01 pm

POET

POET Technologies Inc. announces an additional CAD$10 million private placement financing at CAD$2.90 per unit, involving 3,448,275 units to support its growth phase. The financing includes common shares and warrants, targeting Canadian-based institutional investors without broker fees. This move aims to bolster working capital for the company's optical engine technology demand in AI and high-speed computing markets.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 7:58 pm

PFE

SGEN

The FDA has approved Seagen's Tivdak (tisotumab vedotin-tftv) for the treatment of cervical cancer, according to Bloomberg. This approval marks a significant milestone for Seagen in expanding its portfolio in cancer treatments. Pfizer (PFE), which may have been mentioned in the article, could be involved in this context due to partnerships or collaborations in the development or distribution of Tivdak.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 7:53 pm

SHIBUSD

Shiba Inu (CRYPTO: SHIB) is down 5.3% despite a 144% increase in active accounts and a 73.4% rise in trading volume, indicating growing investor optimism. ShibaSwap's expansion to operate on Shibarium and Ethereum networks, with Bone as the gas fee token, aims to enhance SHIB's utility. The increase in transactions and active accounts, along with a significant portion of SHIB holders in profit, suggests a positive outlook for SHIB despite the current price drop.

Portfolio Pulse from Khyathi Dalal

April 29, 2024 | 7:46 pm

ZS

Investors have shown a bearish stance on Zscaler (NASDAQ:ZS), with options trading revealing 81% bearish sentiment. Benzinga's options scanner identified 11 unusual trades, indicating a price target range of $180 to $250 for ZS. The largest trades include both bearish and bullish positions, with a notable volume and open interest in options within the $180 to $250 strike price range. Zscaler, a cloud-native cybersecurity SaaS firm, has seen its stock price increase by 0.73% to $178.34, with a neutral RSI. Analysts have issued mixed ratings, with a consensus target price of $236.67.

Portfolio Pulse from Benzinga Insights

April 29, 2024 | 7:46 pm